Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

被引：3
|
作者：
Zhao, Shuang [1 ]
Liu, Yanyan [1 ]
Yao, Zhihua [2 ]
Yan, Zheng [3 ]
Yao, Shuna [1 ]
Chu, Junfeng [1 ]
Wang, Haiying [1 ]
Zhang, Jiuyang [1 ]
Zhang, Peipei [1 ]
Zhou, Wenping [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-166829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6579 / 6580
页数：2
相关论文
共 50 条
  • [31] A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
    Chiang, N-J.
    Bai, L-Y.
    Huang, C-J.
    Chen, S-C.
    Hsiao, C-F.
    Shan, Y-S.
    Su, Y-Y.
    Chen, L.
    Chen, M-H.
    ANNALS OF ONCOLOGY, 2021, 32 : S377 - S377
  • [32] A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    De Laurentiis, M
    Palmieri, G
    Marinelli, A
    Colantuoni, G
    Diadema, MR
    De Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
  • [33] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    Becker, M.
    Tschechne, B.
    Reeb, M.
    Schwinger, U.
    Bruch, H. -R.
    Frank, M.
    Strassl, L.
    ANNALS OF HEMATOLOGY, 2015, 94 (09) : 1553 - 1558
  • [34] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    M. Becker
    B. Tschechne
    M. Reeb
    U. Schwinger
    H.-R. Bruch
    M. Frank
    L. Straßl
    Annals of Hematology, 2015, 94 : 1553 - 1558
  • [35] First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 2003, 30 (01) : 9 - 15
  • [36] Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma
    Laura Galvez-Carvajal
    Cristina Quero
    María Casanova
    Carola Díaz
    Jose Reinaldo Chícharo
    Manuel Espeso
    Ángeles Medina
    Inmaculada Ramos
    Emilio Alba
    Antonio Rueda
    International Journal of Hematology, 2022, 115 : 54 - 60
  • [37] Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma
    Galvez-Carvajal, Laura
    Quero, Cristina
    Casanova, Maria
    Diaz, Carola
    Reinaldo Chicharo, Jose
    Espeso, Manuel
    Medina, Angeles
    Ramos, Inmaculada
    Alba, Emilio
    Rueda, Antonio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (01) : 54 - 60
  • [38] Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: A phase I trial
    Meerpohl, HG
    duBois, A
    Luck, HJ
    Kuhnle, H
    Mobus, V
    Kreienberg, R
    Bauknecht, T
    Kochli, O
    Bochtler, H
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S17 - S22
  • [39] Phase II trial of oxaliplatin plus capecitabine as first-line treatment in patients with advanced gastric cancer (AGC)
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Poggi, G.
    Teragni, C.
    Delmonte, A.
    Frascaroli, M.
    Jedrychowska, I
    Canto, A. M.
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI51 - XI52
  • [40] A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K. Dennison
    Samuel A. Jacobs
    John W. Wilson
    Janell Seeger
    Terrence P. Cescon
    Jane M. Raymond
    Charles E. Geyer
    Norman Wolmark
    Sandra M. Swain
    Investigational New Drugs, 2007, 25 : 545 - 551
12345